Picture of AstraZeneca logo

AZN AstraZeneca Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareConservativeLarge CapFalling Star

Momentum

Relative Strength (%)
1m+4.05%
3m-0.4%
6m-7.45%
1yr-9.51%
Volume Change (%)
10d/3m+29.91%
Price vs... (%)
52w High-16.93%
50d MA-0.32%
200d MA-3%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)15.7
PEG Ratio (f)0.33
EPS Growth (f)89.89%
Dividend Yield (f)2.4%
Valuation (ttm)IndustryMarket
Price to Book Value5.19
Price to Tang. Bookn/a
Price to Free Cashflow30.96
Price to Sales4.44
EV to EBITDA17.21

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital11.61%
Return on Equity15.63%
Operating Margin17.88%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m24,38426,61737,41744,35145,81150,652.7854,503.5715.71%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+73.89+27.14+46.76+27.45-3.46+139.57+11.04n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of AstraZeneca EPS forecast chart

Profile Summary

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
June 17th, 1992
Public Since
September 21st, 2007
No. of Shareholders
66,385
No. of Employees
89,900
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
1,550,205,518

AZN Share Price Performance

Upcoming Events for AZN

AstraZeneca PLC at Berenberg UK Corporate Conference

AstraZeneca PLC at Capital Research EuroFocus Conference

AstraZeneca PLC ESG 2023 Highlights Summary Call

AstraZeneca PLC at Exane BNPP Healthcare Conference (Virtual)

AstraZeneca PLC Annual Shareholders Meeting

Q1 2024 AstraZeneca PLC Earnings Release

AstraZeneca PLC Annual Shareholders Meeting

AstraZeneca PLC Investor Day

Q2 2024 AstraZeneca PLC Earnings Release

Similar to AZN

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of Beximco Pharmaceuticals logo

Beximco Pharmaceuticals

gb flag iconLondon Stock Exchange

Picture of BSF Enterprise logo

BSF Enterprise

gb flag iconLondon Stock Exchange

Picture of Celadon Pharmaceuticals logo

Celadon Pharmaceuticals

gb flag iconLondon Stock Exchange

FAQ